JAMP and Alvotech’s Simlandi (biosimilar, adalimumab) Receive Health Canada’s Approval for the Treatment of Inflammatory Diseases
Shots:
- JAMP Pharma has received the marketing authorization from Health Canada for a high-concentration biosimilar to Humira (adalimumab)
- Upon the exclusive commercialization agreement with JAMP Pharma, AVT02 (100 mg/mL) will be marketed as Simlandi in Canada & will provide Canadians access to a biosimilar that is also used across both EU and the US
- Simlandi is a high-concentration, citrate-free biosimilar to Humira & is used to treat inflammatory conditions. Additionally, JAMP Pharma’s commercial infrastructure and expertise will allow Canadian patients to benefit from safe and effective biosimilars along with JAMP Care patient support program
Ref: Alvotech | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
